Crossmark

Scavenger receptor class B1 — a target to reduce CHD risk?

Crossref DOI link: https://doi.org/10.1038/nrcardio.2016.50

Published Online: 2016-04-07

Published Print: 2016-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Barter, Philip J.

Rye, Kerry-Anne
License Information

Text and Data Mining valid from 2016-04-07
More Information

Article History

First Online: 7 April 2016

Competing interests

: P.J.B. declares that he has received research support from Merck and Pfizer, and has acted as a consultant or received honoraria from Amgen, AstraZeneca, Cerenis, CSL-Behring, Dezima Pharmaceuticals, Eli-Lilly, Kowa, Merck, Novartis, Pfizer, and Sanofi-Regeneron. K.-A.R. declares that she has received research support from CSL-Behring, Merck, and Sanofi-Regeneron.